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Abstract 
Anorexia Nervosa (AN) is characterized by a self-imposed starvation and is often 
accompanied by excessive exercise that results in severe malnutrition and sometimes death. 
Behavioural and pharmacological treatments of AN need to be improved. In rats, acute 3 h 
daytime wheel access suppresses ad lib feeding over the subsequent night relative to no wheel 
controls, a phenomenon that has been suggested as an animal model of AN. This acute wheel 
induced feeding suppression (WIFS), can be induced reliably when rats are given limited wheel 
access exposure during the light cycle (Lattanzio & Eikelboom, 2003). The acute WIFS is useful 
because it can be used to test the effects of pharmacological agents, in a paradigm where the 
duration of wheel running and its effects are tightly defined. Chronic chlorpromazine injections 
can minimize the severity of activity anorexia (AA) procedure (Routtenberg, 1968), a related rat 
model of AN (Epling, Pierce & Stephan, 1983), by attenuating wheel running. Experiment 1 
tested the acute effects of a one-time chlorpromazine injection (2 mg/kg IP) on the acute WIFS 
in 40 adult male rats. Animals were divided into five treatment groups (n=8): drug before wheel 
access (DW); drug after wheel access (WD); drug with locked wheel access (DNW); saline with 
locked wheel access (SNW); and saline with wheel access (SW). Half of each of the three 
control groups (DNW, SNW and SW) received injections before wheel access and half were 
injected after the wheel access period. Experiment 2 followed the same procedure except a 
broader range of chlorpromazine doses was tested (0.25, 0.50, 1 and 2 mg/kg). Both studies show 
that while chlorpromazine (at 1 and 2 mg/kg) did not attenuate feeding or wheel running, it 
blocked the acute WIFS. At doses of 0.25 and 0.50 mg/kg chlorpromazine had no effect. 
iv 
Because the pharmacological profile of chlorpromazine implicates the serotonin, histamine and 
dopamine systems in the acute WIFS (and potentially AN), future work should look at drugs 
with more specific modes of action to identify which neurotransmitter systems may be involved. 
The acute WIFS procedure may be useful for screening potential drug treatments for AN, where 
exercise is often elevated and feeding is suppressed. 
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Chlorpromazine and Wheel Running 1 
Anorexia nervosa (AN) is a disorder that is characterized by excessive weight loss caused 
at least partially by reduced eating. Often, this condition is exacerbated by a constant general 
hyperactivity and compulsion to exercise (Attia & Walsh, 2009; Bergh, Erisson, Lindberg & 
Sodersten, 1996; Casper, 2006). It has been observed that up to 85% of AN patients exercise to 
excessive levels throughout the course of the disorder (Davis, 1997) and some argue that the 
relationship between excessive activity and reduced feeding is a key feature of AN. 
Current treatments for AN, most of which are behavioural in nature, are not very 
effective. Of all patients treated, only 46% fully recover, 34% improve and 20% develop a 
chronic form of the disease that, in many cases, leads to death (Steinhausen, 2002). Given the 
unfavourable prognosis of AN patents, it is evident that clinicians need to look beyond the 
traditional 'behavioural' treatment strategies and into other domains, such as the biochemical. 
To explore the biochemical substrates of human disease, researchers commonly turn to animal 
models. 
With respect to AN, many wheel running animal models exist, all of which examine the 
relationship between feeding and exercise when it becomes counterintuitive. One possible 
advantage of such models is that they allow for the study of AN in the absence of the 
psychological and social factors, which may make our understanding of the disease difficult in 
humans. Once it is clear how feeding and exercise interact in AN, researchers will be in a 
position to study how psychological factors might contribute to the development and 
maintenance of this disease. 
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Wheel Running Models of Anorexia Nervosa 
When a rat is given continuous access to a running wheel, it will run and gradually 
escalate its running from about 1 km on the first day up to 5-6 km over a period of a few weeks 
(Eikelboom & Mills, 1988). One interesting consequence of wheel introduction is a 25% self-
imposed suppression in feeding lasting about 7 to 10 days and a chronic reduction in weight 
(Alfonso & Eikelboom, 2003). This has been labelled as the wheel induced feeding suppression 
(WIFS). This phenomenon is counterintuitive because the animals expend more calories running 
and consume less food than non-wheel controls. It has been proposed that this could function as 
a model of an important aspect of AN (Lattanzio & Eikelboom, 2003). 
The animal model of AN that has attracted the most attention is the activity anorexia 
(AA) procedure (Casper, Sullivan & Tecott, 2008; Epling, Pierce & Stephan, 1983). This 
procedure is similar in some ways to the WIFS paradigm. In the AA procedure, wheel 
introduction and food restriction (usually 1 hour of food access a day) are introduced 
simultaneously and result in reduced feeding (relative to food restricted non-wheel controls) and 
increased running (relative to non-deprived controls) which proves fatal for rats within a few 
days (Routtenberg & Kuznesof, 1967). The interpretation of AA is complicated by a number of 
factors inherent to the procedure. Firstly, there is a learning complication in that animals must 
adapt to the experimenter-imposed feeding schedule. Thus, food intake generally increases over 
the first number of days and over cycles of this procedure in a manner that indicates learning 
(Boakes & Dywer, 1997; Hampstead et al, 2003; Lett et al, 2001; Pare et al., 1985). Secondly, 
with food deprivation, wheel running increases significantly (relative to ad lib fed rats) and thus 
energy expenditure is increased (Routtenberg & Kuznesof, 1967). This occurs even if the wheel 
is not novel (Exner et al., 2000; Nergardh et al., 2007). Lastly, at wheel introduction feeding is 
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suppressed both with ad lib and restricted food access (Alfonso & Eikelboom, 2003; Routtenberg 
& Kuznesof, 1967). The feeding suppression induced by the wheel is temporary, both with ad 
lib feeding (Afonso & Eikelboom, 2003) and in the AA procedure (Hampstead et al., 2003). 
The problem in the activity anorexia procedure seems to be that animals do not have enough 
energy reserves to adapt to the various changes before the onset of starvation. It is not clear how 
or if these three factors are connected, or how they interact in the AA procedure, but they 
ultimately may all be important in AN. What is apparent is that the WIFS, because it does not 
involve food deprivation, provides a simpler model that may address specific aspects of the 
feeding-exercise relationship. 
The WIFS seen with voluntary running and ad lib feeding, has many attributes that make 
it a useful animal model of the exercise feeding relationship in AN. Our model is considered to 
have obvious face validity for AN (Willner, 1990), as it reflects the negative relationship 
between exercise and feeding found in the human condition (Attia & Walsh, 2009; Bergh & 
Sodersten, 1996; Casper, 2006). This isomorphic model of AN (Smith, 1989) reflects many 
aspects of the human disorder without specifying its etiology or mechanisms, which remain 
largely unknown but are easier to explore in the animal model. The most obvious benefit to the 
WIFS model is that all of the changes in feeding and running are intrinsically motivated, not 
externally imposed by an experimenter. The rat model shows a similar developmental profile to 
that seen in human AN. For example, prepubescent rats (less than 32 days old), even though 
they run as far as (or further than) their adult counterparts, do not show the typical feeding 
suppression observed when adolescent (36 - 41 days old) and adult (51+ days old) rats are given 
the opportunity to run (Dalton-Jez & Eikelboom, unpublished work). This highlights the 
potential for the WIFS as a model to study AN. 
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One very important characteristic of the WIFS model is that it can be elicited when rats 
are given short-term access to a wheel. It has been shown that 2 h of wheel access during the 
light cycle is enough to trigger this feeding suppression over the next night (Lattanzio & 
Eikelboom, 2003). One key benefit of testing the effects of limited daytime wheel access on 
feeding is that both the wheel and no wheel groups can feed without distraction during the dark 
cycle, when most eating occurs. 
This acute WIFS may prove a valuable procedure for determining the neurochemical 
systems involved in this paradoxical exercise-feeding relationship. Using an acute WIFS model, 
a drug can be given to an animal before, after, or in the absence of, short term daytime wheel 
access, permitting an evaluation of the drug's effect on running, feeding, and the running-feeding 
interaction without the complication of constant wheel access. As drug tests in animal models 
have long been suggested as useful for preclinical drug evaluations (Mc Kinney, 1974), this 
procedure could ultimately lead to our understanding of the biochemical compounds and 
processes involved in AN and potential pharmaceutical treatments. The question that remains 
then, is what class of drugs should be the first explored in the acute wheel running model? 
Foundational research, conducted in the 1960s and 70s with the AA procedure, suggests that the 
antipsychotics might be a good place to start. 
Experimental Foundations 
The deadly relationship between ad lib wheel running and restricted (1 h per day) 
feeding in rats was first discovered in 1954 by Hall and Hanford. Soon after, researchers began 
to try and uncover the neural mechanisms behind AA. Initial work tested the effect of the 
antipsychotic chlorpromazine (CPZ) and the sedative pentobarbital (PTB), on the survival rates 
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of rats in the AA procedure. Routtenberg and Kuznesof (1967) injected rats daily with either 
CPZ (1 mg/kg), pentobarbital (4 mg/kg) or saline immediately after the 1 h feeding period in the 
AA procedure. Food consumption, body weight and wheel running were measured daily. 
Results indicated that pentobarbital was not helpful in improving survival. Rats injected with 
this agent ran excessively, did not adapt to food restriction, lost weight and died (as did non-
injected controls). Chlorpromazine, on the other hand, was effective in significantly reducing 
wheel running and improving survival compared to saline injected control rats, allowing animals 
to stabilize body mass. Specifically, CPZ injected rats survived for the entire duration of the 
study and ran maximally 1500 wheel turns, while the saline injected controls reached exhaustion 
by day 8 and ran roughly 5000 wheel turns. 
Although CPZ at 1 mg/kg improved survival, reducing wheel running compared to the 
saline group, not all rats injected were protected from starvation. In fact, 25% of them still 
perished. To determine the optimum dose of CPZ required to ensure survival of all AA rats, 
Routtenberg (1968) replicated his first experiment using a 2 mg/kg dose of CPZ. Rats were 
given daily IP injections over the course of the study. After 8 days of baseline, animals were put 
on a restricted (lh/day) diet and given ad lib access to either locked or unlocked wheels for 8 
days. Again, wheel running, body weight and food consumption were measured. Data showed 
that 2 mg/kg injections of CPZ improved survival rates, and even more so than those injected 
with 1 mg/kg. Rats injected with 2 mg/kg ran significantly less (about 1000 revolutions by day 
12) than those with only 1 mg/kg (roughly 3000 revolutions by day 12) and weighed about 25 g 
more. Interestingly though, the group injected with the higher dose of CPZ and with the higher 
survival rate, ate less than the 1 mg/kg group over the first 10 days of the experiment. One 
explanation for this might be that, at higher doses, CPZ produces a conditioned taste avoidance 
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(CTA), as described by Parker (2003), that enhances the feeding suppression observed when rats 
are introduced to the AA paradigm. 
Taken together, these findings suggest that CPZ, a typical antipsychotic, can help animals 
cope in the AA paradigm by reducing activity. They also suggest that 2 mg/kg might be the 
optimum dose, as it seems to be the minimum required to ensure that 100% of the animals 
survive. These findings make it tempting to suggest CPZ as a potential treatment for AN, 
however it would be premature to do so. Although Routtenberg's studies answer many questions 
about the effect of CPZ on activity in the AA procedure, it is unclear how feeding is effected. 
This is especially true since the animals are externally food deprived, unlike in AN where the 
feeding suppression is self imposed. Furthermore, it is not clear why the CPZ injected rats ate 
less than the saline injected group. Was it because CPZ directly effected feeding? Or was it 
because CPZ impaired the animal's ability to learn? Unfortunately it is impossible to tease these 
two possibilities apart using the AA model alone. Moreover, as wheel access is continuous 
(except for feeding time) it is not clear when the drug should be administered to have the most 
effect, especially since CPZ's half life is known to range from 16 - 30 h when injected in 
humans (Yeung et al., 1993). In these early studies by Routtenberg's group, CPZ or saline was 
injected immediately after the 1 hour feeding period. Thus, administration was far removed from 
the next meal and could have resulted in learned taste avoidance (Parker, 2003). This could 
indirectly prevent a recovery of feeding, making it difficult to distinguish the avoidance from 
drug-induced reduction. 
To address the limitations of the AA model and to answer the lingering questions from 
Routtenberg's important groundwork, it would be interesting to explore the effects of CPZ on the 
acute WIFS model. Using this paradigm the effect of CPZ on running, feeding and the running-
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feeding interaction could be specifically identified. By testing similar doses to those used by 
Routtenberg we have a reference data set to which we can compare and contrast. This presents a 
great opportunity for us to build on historical work and take it to the next level. One point worth 
mentioning is the fact that during Routtenberg's time little was known about the effects of 
antipsychotics on feeding and weight gain. Today however, this is not the case and it may be 
useful to discuss the affects of antipsychotics, specifically chlorpromazine, on weight. 
Chlorpromazine 
Chlorpromazine (2-chloro-10-(3-dimethylaminopropyl-phenothiazine) represents one of 
the earliest known and clinically prescribed antipsychotics. In 1955 it was approved in the 
United States and the effect of this drug in emptying mental hospitals has been compared to that 
of penicillin on infectious disease (Turner, 2007). 
CPZ affects a variety of receptors in the central nervous system, having 
antidopaminergic, anti antiserotonergic and antihistaminic properties which are discussed in 
detail below. Interestingly, CPZ tends to have a higher affinity at serotonin receptors than at 
dopamine receptors, which is the opposite effect of most other typical antipsychotics. Therefore, 
CPZ behaves more like an atypical antipsychotic in terms of its dopamine and serotonin activity 
(McKim, 2007). CPZ could help treat patients with AN by reducing the rewarding aspects of 
excessive exercise and starvation, through antagonizing the Dl, D2, D3 and D4 receptors 
(Friedman, 1996), and by increasing appetite and feeding through blocking the HI and 5-HT2C 
receptors, respectively (Ravussin, Lillioja & Knowler, 1988; Gothelf, et al., 2002). 
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Antipsychotic Pharmacology: Antipsychotic action and Weight Gain 
Antipsychotic drugs (also referred to as neuroleptics) are a group of psychoactive 
compounds that treat psychosis. Antipsychotics are lipophilic antagonists that effect behavior by 
binding to postsynaptic dopamine, serotonin and histamine receptors (amongst others) in 
different regions of the brain. Each antipsychotic has a slightly different pharmacologic profile 
but all block D2 receptors in the dopamine pathway causing dopamine to have less of an affect. 
Excess release of dopamine in the mesolimbic pathway has been correlated with psychotic 
disorders, such as schizophrenia, and these drugs are very effective at controlling symptoms 
(Friedman, 1996). In fact, an almost perfect correlation exists between the therapeutic dose of an 
antipsychotic and the drugs affinity for the D2 receptor. Therefore, a weak antagonist requires a 
larger dose to control psychotic symptoms and vice versa (Jones & Pillowsky, 2002). 
The first class of antipsychotics (known as typical antipsychotics) involved the discovery 
of CPZ's affects in the 1950s. These early drugs, although effective in reducing psychotic 
symptoms, produce a number of serious side effects including weight gain. A second generation 
of drugs, called the atypical antipsychotics, has since been developed. Atypical antipsychotics, 
such as olanzapine, treat psychosis with fewer side effects but still lead to obesity (Allison et al., 
1999). 
Antipsychotic induced weight gain is caused by both a reduction in energy expenditure 
(Ravussin et al., 1988) and an increase in food intake (Gothelf et al., 2002). Support for this 
comes from reports that demonstrate lower than predicted resting energy expenditure in people 
taking antipsychotic drugs compared to age matched healthy and schizophrenic controls not 
taking the drug (Sharpe et al., 2005). A recent study demonstrated that patients taking clozapine 
(an atypical antipsychotic) burn 20% less energy and consume 20% more calories than the World 
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Health Organization's daily recommendations (Sharp et al., 2006), suggesting it as a possible 
treatment for AN. 
Two receptors that are robustly associated with weight are the serotonin 2C (5-HT2C) 
and histamine 1 (HI) receptors. Chronic agonistic activation of the serotonin receptor decreases 
feeding and feeding behavior (De Vry & Schreiber, 2002), while blocking the receptor 
chronically induces food intake, despite satiety, leading to weight gain (Meguid et al.,2000). It 
is thought that antipsychotics lead to weight gain by chronically antagonizing the central 5-
HT2C receptors which cause patients to overeat, regardless of the sensation of satiety (Reynolds, 
Hill & Kirk, 2006) Histamine receptors are also linked to appetite. Appetite is increased by the 
chronic antagonism of the central HI receptors (Wirshing et al., 1999). Interestingly, the 
different receptor affinity of antipsychotics to 5-HT2C and HI are correlated with their weight 
gain potential. For instance, clozapine and olanzapine (typical antipsychotics), which have the 
highest affinity for 5-HT2C and HI induce the greatest weight gain. In contrast, Risperidone 
(another typical antipsychotic) has a lower affinity for the 5-HT2C and HI receptors, causing 
lesser weight gain (Virk et al., 2004). Although the 5-HT2C and HI receptors are the most 
robust biological factors contributing to weight gain, the role of other neuroendrocrine factors 
such as ghrelin, leptin, orexin and prolactin is unclear (Rege, 2008). Further research is required 
to uncover their mechanisms and thus we will leave them out of further discussion. 
To date, there is an enormous body of research identifying the medical properties of 
antipsychotics and their effects on brain chemistry and behavior (see Parraga, 2007 for a 
comprehensive example) but it is unclear how these drugs effect energy balance in patients with 
AN. To gain insight into this question (and to better understand the neural substrates of the 
wheel running rat model) the effects of CPZ on feeding, exercise and the interaction of these two 
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variables in the acute WIFS paradigm will be investigated. 
The Current Study 
It has long been evident that antipsychotic drugs commonly induce weight gain as a side 
effect (Allison et al., 1999). There has been speculation as to whether these drugs could help in 
the initial phases of AN treatment, because of their weight gain inducing qualities and the 
possible alleviation of associated psychological symptoms (fear of fatness, misperception of 
body mass). Recently, a randomized, double blind, placebo controlled trial of olanzapine, an 
atypical antipsychotic, was conducted using female AN patients as participants (Bissada et al., 
2008). Olanzapine use resulted in increased weight gain and lessening of obsessive symptoms 
and has been suggested as a valuable option for the initial, short term phase of treatment. In light 
of these results, it would be prudent to test antipsychotics in the acute WIFS procedure. 
In the current study CPZ, the typical antipsychotic, was evaluated using the acute WIFS 
procedure. This was the first of many drugs tested in the activity anorexia procedure 
(Routtenberg, 1968; Routtenberg & Kunzesof, 1967; Woods & Routtenberg, 1971). Chronic 
administration of CPZ in the activity anorexia paradigm reduces wheel running and so indirectly 
decreases the severity of the procedure. While these studies do provide a model in which to test 
drugs, the model is limited by the aforementioned complications of the AA procedure. In the 
current study, the acute WIFS model is used to evaluate the impact of acute CPZ on feeding, 
running, and the WIFS. Based on chronic work, it may be that CPZ (and similar drugs) directly 
stimulates or suppresses feeding which would then be evident in non-wheel controls. 
Alternatively, it may directly reduce activity and thus indirectly prevent the WIFS, tested by 
comparing groups given the drug before or after the limited wheel exposure. A third more 
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interesting possibility is that the exercise-feeding suppression dyad may be prevented by this 
drug. Such a drug would then target the relationship between running and feeding without 
increasing eating in non-exercising control animals or decreasing exercise, specifically removing 
the threat of this harmful relationship. If this dyad is an important aspect of the etiology of AN, 
it would suggest this class of drugs might prove useful in treatment of this puzzling disorder. 
Experiment 1: As published by Adams, Parfeniuk & Eikelboom, 2009 
Method 
Subjects 
Fourty male Sprague-Dawley rats (Charles River Canada, St. Constant, Quebec, Canada) 
weighing 200-225 g (47-49 days old) upon arrival were housed individually in standard shoebox 
cages (20 x 24 x 45 cm) and maintained on a 12 hour light/dark cycle, with lights on at 0700 
(7:00 AM). Colony conditions were kept stable (50% relative humidity, 21-22 °C), and food and 
tap water were available ad libitum throughout the study. All experimental procedures were 
approved by the Wilfrid Laurier University Animal Care Committee which follows the policies 
and guidelines of the Canadian Council on Animal Care. 
Apparatus 
Wheel access was given in Nalgene™ running wheels (33 cm diameter and 11 cm wide) 
inserted in standard shoebox cages. These wheels could be locked using two paper clamps 
clipped between the rungs on the outside of the Nalgene wheel to prevent wheel turning. Wheel 
turns were counted to a resolution of 1 s using a magnetic closure system and the VitalView™ 
Minimitter Co. Ltd. software package. 
Drug and doses 
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Chlorpromazine solution (CPZ, as chlorpromazine hydroxide, Sigma Aldrich, St. Louis, 
MO) was prepared fresh on each injection day in sterile isotonic saline at a dose of 2.0 mg/kg. 
CPZ was injected intraperitoneally (IP) at a volume of 1 ml/kg. The control rats that did not 
receive CPZ received equivalent injections of saline. 
Procedure 
Baseline measures of food consumption, water consumption and weight were taken daily 
at about 1430 (2:30 PM). Food consumption was measured by dumping the food pellets from the 
lid of each cage into separate plastic dishes and weighing them on a digital scale that was 
accurate to one tenth of a gram. Daily food consumption was determined by calculating the 
differences in food weight from one day to the next. Small crumbs and food particles were 
ignored, as in previous work they have been found to weigh less than 1 g, and not to vary across 
conditions. Rats initially received 300 g of food at the start of the experiment and were topped 
up to this amount once their total available food volume fell below 200 g. Water bottles were 
weighed daily, also at around 1430, and the difference from one day to the next indicated how 
many ml each rat consumed. Once a bottle fell below half of its capacity (which was about 600 
ml) it was topped up. Body weight was measured daily between 1430 (2:30 PM) and 1530 (3:30 
PM). After 7 days of baseline, all 40 rats were moved into wheel cages for 24 h to establish a 
baseline running level, measure the WIFS seen with one day of ad lib wheel access and provide 
rats familiarity with the wheel. The rats were then assigned in a way to equalize for feeding 
suppression (day before wheel running - the day after wheel running), distance run (wheel turns) 
and body weight (g) into 5 groups of 8. Twenty-four h after the wheel exposure period rats were 
rank ordered from smallest to largest in terms of their WIFS and then distributed to 1 of the 5 
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treatment groups in the following manner: Rat 1 into group 1, Rat 2 into group 2, Rat 3 into 
group 3, Rat 4 into group 4, Rat 5 into group 5, Rat 6 into group 1, Rat 7 into group 2, Rat 8 into 
group 3 etc. After all the rats had been distributed in terms of their WIFS an analysis of variance 
(ANOVA) was completed to ensure that none of the groups differed in terms of their WIFS, 
wheel turns or body weight. If any groups differed at this point the animals were shifted around 
using feeding and weight data until all groups were equal. 
The five groups were the drug before wheel access (DW); drug after wheel access (WD); 
drug with locked wheel access (DNW); saline with locked wheel access (SNW); and saline with 
wheel access (SW). Half of each of the three control groups (DNW, SNW and SW) received 
their injections before wheel access and half were injected after the wheel access period (a 3 
group by 2 injection time ANOVA revealed no significant differences in feeding on the critical 
day due to injection time, so the two sub-groups for each group were combined for the final 
analysis). 
Three days after the 24 h baseline wheel exposure, animals injected before wheel access 
received the appropriate IP injections, either saline or CPZ, at approximately 1500 and were 
placed back into their home cages. Thirty minutes after their injection (about 1530), all rats were 
placed in the wheel cages, with the wheel unlocked for wheel access or locked for novel 
environment only groups, and remained there for 3 h (during which food was not accessible). 
The rats were then placed back in their home cages 30 min before the lights went out. Groups 
that received their injection after wheel access were injected immediately after being removed 
from the wheel cage. Each rat received only one injection. Food consumption over the next 22 
hours was measured as the critical dependent variable. 
Results 
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Initial 24 h baseline access 
Figure 1 shows wheel turn data over the 24 h baseline running period. Because of the 
way the animals were assigned a 5 group ANOVA revealed that the experimental groups did not 
differ significantly. Wheel turns in this period did not correlate with later 3 h running, or with the 
decrease in feeding induced by the 24 h of this baseline wheel access. 
Figure 2 shows food consumption for the day before and the day after wheel access (24 
h). Data was analyzed using a 5 group by 2 day mixed ANOVA which revealed an overall 
significant feeding suppression [F(l,35) = 52.26, p < .001], but again, because rats were 
assigned to groups based on their feeding suppression, the groups did not differ. Rats ate 29.8 ± 
.52 (SEM) g the day before the 24 h wheel access and 25.0 ± 0.58 g over the 24 h of wheel 
access. 
Running on injection days (3 h wheel access). 
A 3 group ANOVA revealed that the wheel groups (DW, WD, SW) did not differ 
significantly in their running over the three hours of wheel access, as measured in wheel turns 
(see Figure 3). 
Feeding after injection and 3 h wheel access. 
Figure 4 depicts feeding over the 24 h after injection of CPZ or saline before or after 3 h 
access to a locked or unlocked wheel. Overall, the 5 group ANOVA revealed the food 
consumption of the groups differed significantly [F (4,35) = 3.82, p < 0.05]. A Newman-Keuls 
post hoc test found that only the saline injected, wheel exposed rats (Group SW) ate less than the 
rats in the other four groups,/* < 0.05. 
Chlorpromazine and Wheel Running 15 
In the three wheel groups, feeding suppressions (difference between the 24 h before 
wheel access and the 24 h afterwards) differed [F(2,2\) = 18.49, p < 0.001]. Again, post hoc 
tests show that the SW group was responsible for this effect, being the only wheel group that 
showed a feeding suppression (data not depicted). 
There was also no correlation between number of wheel turns and feeding in the 24 h 
after 3 h wheel exposure (for the 24 rats with wheel access the Pearson r = -0.039). 
Discussion 
Experiment 1 suggests that 2 mg/kg of CPZ specifically prevents the interaction of 
running and feeding in the acute WIFS paradigm. This is true since CPZ did not elevate feeding 
in the DNW group relative to the SNW group or reduce running in the DW group relative to the 
WD group but did block the running-feeding interaction (in the DW and WD groups compared 
to the SW group). These results are very interesting and suggest CPZ may be useful in 
identifying the neural substrates of the WIFS (and potentially AN). Before we can begin to 
understand how CPZ may act as a possible treatment for the acute WIFS paradigm and thus AN, 
more questions need to be resolved: First, are these results repeatable? Second, what minimum 
dose is required to observe this effect? And finally, is this a dose dependent or an "all or none" 
effect? Experiment 2 was designed to answer these questions. 
Experiment 2 
Methods 
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Subjects 
Sixty-four male Sprague-Dawley rats (Charles River Canada, St. Constant, Quebec, 
Canada) were housed in standard shoebox cages (20 x 24 x 45 cm) and kept on a 12 h light-dark 
cycle, with lights on at 1200 (noon). Colony conditions were kept stable (50% relative humidity, 
21 - 22°C), and food and tap water were available ad libitum throughout. The animals had a 
history of saccharin consumption from a previous experiment and were therefore given 10 days 
to acclimatize to their "non-saccharin" diets before baseline food and water measures 
commenced. The animals weighed between 450 - 550 g at the start of the experiment and all 
treatment groups were counterbalanced with respect to saccharin history. All experimental 
procedures were approved by the Wilfrid Laurier University Animal Care Committee which 
follows the policies and guidelines of the Canadian Council on Animal Care. 
Apparatus 
The equipment used here were the same as in Experiment 1. 
Drug and doses 
Chlorpromazine solution was prepared fresh on each injection day in sterile isotonic 
saline at doses of 2.00, 1.00, 0.50 and 0.25 mg/kg. CPZ was injected intraperitoneally (IP) at a 
volume of 1 ml/kg. The control rats that did not receive CPZ received equivalent injections of 
saline. 
Procedure 
Baseline measures of food consumption, water consumption and weight were taken daily 
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at about 1500. Food, water and wheel turn data were collected using the same procedures as in 
Experiment 1. Due to equipment limitations, Experiment 2 was conducted in two equivalent 
replications of 32 rats. After collecting 7 days of baseline data (food consumption [g] and body 
weight [g]), rats were given 24 h of wheel access to establish baseline levels of running, measure 
the WIFS seen with one day of ad lib wheel access and provide rats with familiarity to the wheel. 
The rats were then randomly assigned to equalize wheel running and feeding suppression to 8 
groups of 8: 2 mg/kg drug before wheel access (2-DW); 2 mg/kg drug after wheel access (2-
WD); 1 mg/kg drug before wheel access (1-DW); 0.5 mg/kg drug before wheel access (.5-DW); 
0.25 mg/kg before wheel access (.25-DW); 2 mg/kg drug with locked wheel access (2-DNW); 
saline with locked wheel access (SNW); and saline with wheel access (SW). 
Three days after the 24 h baseline wheel exposure, animals injected before wheel access 
received the appropriate injections, either saline or CPZ, at approximately 1800, 4 h before lights 
out. Thirty minutes after their injection (about 1830), all rats were placed in wheel cages, with 
the wheel unlocked for wheel access or locked for novel environment only groups, and remained 
there for 3 h. The rats were then placed back in their home cages. Groups that received their 
injection after wheel access were injected immediately after being removed from the wheel cage. 
Each rat received only one injection. Food consumption over the next 24 h was measured as the 
critical dependent variable. 
Initial 24 h baseline access 
Results 
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Since animals were assigned to groups to equalize distance run, an 8 group analysis of 
variance (ANOVA) revealed that the groups did not differ significantly in wheel turns over the 
baseline day (see Figure 5). Similar to Experiment 1, the distance run over the initial 24 h wheel 
access did not correlate with later 3 h running, or with the decrease in feeding induced by the 24 
h wheel access. 
An 8 group by 2 day mixed ANOVA looking at food consumption (g) on the test day, 24 
h after the 3 h wheel exposure, revealed an overall significant effect on feeding [F(l,56) = 552.9, 
p < 0.001] and that none of the treatment groups differed. This indicates that the experimental 
groups were successfully balanced for their level of feeding suppression. Rats consumed 36.8 ± 
0.52 (SEM) g the day before wheel access and 31.0 ± .58 g over the 24 h of wheel access (see 
Figure 6). 
Running on injection days (3 h access). 
The 5 group ANOVA revealed that the 5 wheel groups (.25-DW, .5-DW, 1 -DW, 2-DW, 
2-WD) did not differ significantly in their running over the three hours of wheel access, as 
measured in wheel turns (see Figure 7). There was also no significant correlation between the 
number of wheel turns and feeding in the 24 h after 3 h wheel exposure (for the 40 rats with 
wheel access the Pearson r = -.167). 
Feeding after injection and 3 h wheel access. 
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Figure 8 shows feeding over the 24 h after injection of CPZ (at 2.00, 1.00, 0.50 or 0.25 
mg/kg) or saline before or after 3 h access to a locked or unlocked wheel. Overall, the 8 group 
ANOVA revealed a significant main effect on feeding [F(7,55) = 5.292, p < .001]. A Newman-
Keuls post hoc test revealed that the SW group ate less than the SNW, 1-DW, 2-DW, 2-WD and 
2-DNW groups and that the .25-DW and .5-DW groups ate an intermediate amount of food 
compared to the SW and 2-DW/2-WD groups. 
Discussion 
Two mg/kg of CPZ prevented the acute WIFS, replicating the effects observed in 
Experiment 1. It was also determined that a dose of 1 mg/kg may be the minimum required to 
prevent a feeding change when rats gain access to the wheel. Furthermore, Experiment 2 
revealed that the effects of CPZ on the acute WIFS are dose dependent (and not "all or none"). 
General Discussion 
The Present Study 
Using the WIFS, a simple model that focuses on a specific aspect of the AA procedure, 
we are able to dissect some of the links between exercise and feeding. In particular this acute 
WIFS procedure can be used as a simple screen to assess the acute behavioural effects of drugs, 
in this case CPZ, and elucidate how the drug works to impact feeding in the WIFS. In this 
procedure, the direct effect of the drug on feeding is evident in the comparison between the 
saline and drug groups that did not have wheel access. In the present study it was shown that 
acute injections of CPZ have do not directly effect feeding. The comparison between the two 
saline groups with and with out wheel access demonstrates that the procedure supports a feeding 
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suppression. Further comparison of rats receiving CPZ before or after wheel access 
demonstrated that drug had no effect on acute daytime wheel running. Finally the comparison of 
the CPZ wheel groups with the CPZ no wheel group demonstrated that the drug prevents the 
acute WIFS. 
Chlorpromazine's effect on wheel running in the Acute WIFS 
Based on Routtenberg's chronic work (1967), it may be expected that the DW groups 
would have run less than the SW and WD groups, but this was not the case. In fact, all wheel 
groups, regardless of their injection history, ran equivalent distances. Reasons for this are not 
totally clear. Simply stated, it might be that CPZ, when injected acutely, does not affect wheel 
running. A second possibility however, could be that the acute WIFS model, which permits only 
3 h of daytime wheel access, is not sensitive enough to detect running differences when CPZ is 
injected between 0 and 2 mg/kg. Perhaps in future studies, daytime wheel access duration 
should be extended. This might allow for running differences to be revealed (or completely 
ruled out), while preserving the model's key strength - which is to determine the effect of drugs 
on running, feeding and the running feeding interaction. 
In the acute WIFS model, it is interesting how little daytime running, around 400 wheel 
turns, is necessary to suppress feeding over the subsequent night. This is consistent with 
previous work that 2 h of daytime wheel access can suppress feeding as much as ad lib wheel 
access (Lattanzio & Eikelboom, 2003) and that no correlation exists between running and the 
feeding suppression (Afonso & Eikelboom, 2003). To date, most animal studies of AN have 
focused on the effects of food restriction on wheel running in the AA model, which becomes 
excessive. The current model however looks directly at the opposite; the effects of limited wheel 
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access on feeding. In this case, excessive wheel running is not critical to the model, a 
phenomenon that enables us to test the effects of drugs specifically on the running feeding 
interaction. 
Chlorpromazine's effect of feeding in the acute WIFS 
In the present experiments, animals that received a saline or a low dose CPZ injection 
(less than 1 mg/kg), either before or after wheel access, were the only animals that showed the 
anticipated feeding suppression. At doses equal to or greater than 1 mg/kg, CPZ prevented the 
feeding suppression when injected either before or after wheel exposure. That the non-wheel 
CPZ injected controls did not eat significantly more than the saline control animals indicates that 
the drug, when injected acutely, does not increase appetite or food intake overall. This is 
contrary to what is observed when CPZ is administered chronically (Allison et al., 1999). 
Reasons for this are unclear. It might be that the effects of CPZ on the serotonin and histamine 
systems (and thus feeding and weight gain) change with repeated exposure. To understand what 
is happening, researchers will have to identify the physiological changes that accompany chronic 
CPZ exposure. Do the feeding centers in the brain become more sensitive to the antagonizing 
effects of CPZ? Are specific receptors up or down regulated? Answers to these questions may 
be important in helping us understand feeding, and pathologies of feeding. 
In the current experiment running did not differ significantly between the groups so it 
appears this acute CPZ administration did not decrease activity and in this way circumvent the 
WIFS phenomenon. Results from Experiment 2, our dose-response analysis of CPZ effects on 
the acute WIFS, suggest that there may be an 'optimal dose range' that does not significantly 
reduce running with acute application, but does prevent the WIFS. Although we cannot confirm 
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the upper end of this 'optimal dose range', it appears that 1 mg/kg may be the minimum 
required. 2 mg/kg was chosen to mirror previous work with CPZ in AA, in which 2 mg/kg were 
used (Routtenberg, 1968; Routtenberg & Kuzeneof, 1967; Woods & Routtenberg, 1971). It 
appears that CPZ targets the relationship between feeding and activity in the running wheel, 
specifically uncoupling them to avoid the counterintuitive reduction in feeding that often 
accompanies running. The exact biochemical mechanisms underlying these results are not yet 
clear but hypotheses can be made. 
Why might Chlorpromazine prevent the running feeding interaction? 
Currently the biological underpinnings of the WIFS are unknown. Based on the present 
results however, combined with related literature, a working hypothesis can be deduced. Bouts 
of exercise, both voluntary wheel running (Lattanzio & Eikelboom, 2003) and forced treadmill 
exercise (Oscal, 1973), are known to increase the activity of the central serotonin (Jacobs, 1994; 
Chaouloff, 1997), histamine (Ransford, 1982) and dopamine (Dunn et al., 1996) systems in rats. 
Following wheel introduction, rats show a temporary feeding suppression compared to non-
running controls, a finding that has been consistently reported in AA (Lett & Grant, 2001), WIFS 
(Lattanzio & Eikelboom, 2003) and acute WIFS (Adams & Eikelboom, unpublished work) 
procedures. From these results it can be proposed that running and feeding may interact via the 
serotonin and histamine systems. To investigate this further, more specific agonists and 
antagonists need to be tested. Running may cause a feeding suppression through the release of 
serotonin and histamine, which in turn act on the 5-HT2C and HI receptors, respectively, to 
reduce appetite and food intake. This is supported by the widely accepted notion that 5-HT and 
histamine pathways play a fundamental role in energy balance (Vickers et al., 2000). Dopamine 
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is also released during wheel running (Dunn et al., 1996) and may play a significant role in 
reinforcing these maladaptive behaviours, encouraging them to potentially propagate to 
dangerous levels, like in the model AA or AN itself. 
If this theory is accurate it may explain how CPZ acts to specifically prevent the feeding 
suppression in the acute WIFS model. At doses of 1-2 mg/kg, CPZ potentially antagonizes the 
5HT2C and HI receptors, enough to counteract the suppressive effects of running on appetite and 
feeding, but not enough to increase feeding in the drug injected non-running control rats. The 
antidopaminergic properties of CPZ might also have helped by reducing the rewarding aspects of 
engaging in these counterintuitive behaviours. This framework then, highlights at least three 
systems that may potentially be involved in the WIFS, AA and AN. 
To identify more specifically the potential roles of the serotonin, histamine and dopamine 
systems in the WIFS, future work could test drugs that act specifically on a single receptor type 
in the acute WIFS paradigm. For example, it would be interesting to independently test the 
effects of the specific 5-HT2C serotonin antagonist SB-242084 (Kennett et al, 1997), the 
dopamine D2 receptor blocker pimozide (Lambert & Porter, 1992), and the HI receptor 
antagonist doxepin (Kanba & Richelson, 1983) to see how each of these would effect running 
and feeding in the acute WIFS model. Results from such studies would indicate which receptor, 
or combination of receptors, is important in preventing the interaction between running and 
feeding in rats. This in turn could help uncover the neurochemical substrates of the WIFS and 
potentially AN. 
It should be noted that the above explanation presents a simplified view of the complex 
biochemical reactions that likely take place in the WIFS, AA and AN. The purpose of this 
discussion is to provide a foundation on which future hypotheses can be tested. There are likely 
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many factors and neurochemical systems contributing to the counterintuitive relationship that 
sometimes exists between feeding and exercise, only a few of which are touched on here. 
Future Avenues of Exploration 
To date, most clinical therapies of AN involve the administration of selective serotonin 
reuptake inhibitors, which are effective in treating the psychopathology but are ineffective in 
producing weight gain (Bergh et al., 1996). These results are puzzling, especially since 5-HT2C 
receptor antagonists are known to induce weight gain in non-anorexic humans (Meguid, Fetissov 
& Verma, 2000), and suggest that serotonin may not play a major role in linking exercise to 
feeding, at least in underweight AN patients. It would be interesting to test the effects of specific 
serotonin reuptake inhibitors on feeding and wheel running in the acute WIFS model. Results 
from such studies would help increase the models validity if they paralleled those observed in a 
human clinical setting. 
A more interesting direction however, might be to test the effects of specific HI 
antagonists on the acute WIFS. Results from this work may implicate the central histamine 
system as being the major biological link between feeding and exercise in wheel running rats, 
and potentially AN. The central histamine system has long been implicated in feeding. Central 
histaminergic activity is increased by food intake after starvation (Itoh, Oishi & Saeki, 1991) and 
HI receptor concentration is correlated with food intake, particularly in low protein diets 
(Mercer, et al. 1994). Interestingly, AN patients have recently been found to have higher central 
HI receptor densities compared to that of healthy controls participants (Yoshizawa et al., 2009). 
Identifying the effects of specific HI antagonists on rats in the acute WIFS model could help 
validate the model and lead researchers to explore this exciting avenue. 
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The current experiment using the WIFS model involved acute, one time exposure to the 
drug, prior to application of an AN model. While the acute condition is valuable for screening 
this and other drugs for effectiveness, in reality, these drugs would be given chronically to 
humans. Thus, further study involving chronic access to CPZ and repeated access to the wheel is 
needed. 
Prior work has suggested that 2 h a day of daytime wheel access produces a feeding 
suppression that lasts for 7 to 10 days (Lattanzio & Eikelboom, 2003), so this experimental 
protocol can be used to test drugs in a more chronic application. Also, rats could be injected 
with CPZ (or the drug of interest) several days before wheel access, a strategy that has been used 
effectively in the past (Routtenberg, 1968). Based on the early work (Routtenberg, 1968; 
Routtenberg & Kuzeneof, 1967; Woods & Routtenberg, 1971), it might be expected that with a 
higher CPZ dose or chronic administration of the drug, that the drug before and drug after wheel 
groups might differ in wheel running. 
Conclusions 
The present study suggests that injections of CPZ can eliminate the negative interaction 
between feeding and exercise observed in the acute WIFS preparation. Although these finding 
may prove helpful in identifying the neurochemical substrates of the WIFS and ultimately AN, 
they may raise more questions than answers. For example, although we have discovered that 
CPZ prevents the WIFS, the specific neurochemical actions of the drug that cause this effect can 
only be speculated upon. Here we have described the potential role of the serotonin, histamine 
and dopamine systems, the first two of which are linked to feeding and the latter to motivation 
and reward. Currently, it is not clear if it is CPZ's effect on one, two or all three of these systems 
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that is important in preventing the WIFS. To understand this, multiple studies would need to be 
conducted testing a battery of drugs that bind to a specific complement of these receptors. This 
would allow researchers to determine which receptors and brain regions are important in 
preventing the negative interaction between feeding and running observed in wheel running rats 
(and potentially in AN). Furthermore, once a drug has been identified that specifically acts on 
the receptors sites involved in the WIFS, researchers will have to investigate the effects of 
chronically administering this drug. Also, as AN is predominantly observed in women, our 
results need to be replicated in female rats. 
The current experiments suggest that the acute WIFS paradigm may act as a legitimate 
"drug screening" model for AN but there are many challenges ahead. To develop this model 
further would require a massive time commitment and money investment. Although the 
resources to continue this work are not currently available, the goal of this project was to identify 
the potential for an acute "pre-clinical" rat model of AN to give us insight on how to treat 
patients more effectively. 
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Figure Captions 
Figure 1. Mean (±SEM) wheel turns over the initial 24 h wheel exposure. Animals were 
assigned to the chlorpromazine-wheel (DW), wheel-chlorpromazine (WD), saline-wheel (SW), 
chlorpromazine-locked wheel (DNW) and saline-locked wheel (SNW) groups to balance for 
distance run. 
Figure 2. Mean (±SEM) food consumption (g) over the 24 h before (PreWheel) and after 
(PostWheel) the initial 24 h wheel exposure. Rats were assigned to the chlorpromazine-wheel 
(DW), wheel-chlorpromazine (WD), saline-wheel (SW), chlorpromazine-locked wheel (DNW) 
and saline-locked wheel (SNW) groups based on their level of feeding suppression. 
Figure 3. Mean (±SEM) wheel turns (3 h access, paired with an injection). No significant 
differences existed between any of the chlorpromazine-wheel (DW), wheel-chlorpromazine 
(WD), saline-wheel (SW). 
Figure 4. Mean (±SEM) food consumption (g) in the 24 h following chlorpromazine (D) or 
saline (S) injection and 3 h of wheel (W) or locked wheel (NW) access. Group DW was injected 
before, whereas group WD was injected after wheel access. * Significantly different from other 
four groups (NewmanKeuls/><.05). 
Figure 5. Mean (±SEM) wheel turns over the initial 24h wheel exposure. The 2 mg/kg 
chlorpromazine-wheel (2-DW), wheel-2 mg/kg chlorpromazine (2-WD), 1 mg/kg 
chlorpromazine-wheel (1-DW), .50 mg/kg chlorpromazine-wheel (.5-DW), .25 mg/kg 
chlorpromazine-wheel (.25-DW), saline-wheel (SW), saline-locked wheel (SNW) and 2 mg/kg 
chlorpromazine-locked wheel (2-DNW) groups were balanced for distance run. 
Figure 6. Mean (±SEM) food consumption (g) before (PreWheel) and after (PostWheel) the 
initial 24 h wheel access. The 2 mg/kg chlorpromazine-wheel (2-DW), wheel-2 mg/kg 
chlorpromazine (2-WD), 1 mg/kg chlorpromazine-wheel (1-DW), .50 mg/kg chlorpromazine-
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wheel (.5-DW), .25 mg/kg chlorpromazine-wheel (.25-DW), saline-wheel (SW), saline-locked 
wheel (SNW) and 2 mg/kg chlorpromazine-locked wheel (2-DNW) groups were balanced for 
their level of feeding suppression. 
Figure 7. Mean (±SEM) wheel turns (3 h access paired with an injection) No significant 
differences between the 2 mg/kg chlorpromazine-wheel (2-DW), wheel-2 mg/kg chlorpromazine 
(2-WD), 1 mg/kg chlorpromazine-wheel (1-DW), .50 mg/kg chlorpromazine-wheel (.5-DW), .25 
mg/kg chlorpromazine-wheel (.25-DW), saline-wheel (SW). 
Figure 8. Mean (SEM) food consumption (g) in the 24 h following chlorpromazine (D) or saline 
(S) injection and 3 h of wheel (W) or locked wheel (NW) access. Group DW was injected 
before, whereas group WD was injected after wheel access. The SW group consumed 
* significantly less then all groups except the 5-WD and .25-WD (which consumed intermediate 
amounts, statistically equal to all other groups) as per the NewmanKeuls post hoc, p<.05. 
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Figure 5 
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Figure 6 
Food Consumption 
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Figure 7 
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Figure 8 
Food Consumption 
(Test Day: Experiment 2) 
3 
c 
o 
CL 
E 
c 
o O 
• D 
O 
O 
LL 
30 H 
25 H 
20 H 
2-DW 2-WD 1-WD 
T r 
.5-WD .25-WD SW NWS 2-DNW 
Groups 
